What should I eat after capmatinib resistance?

Capmatinib is a targeted therapy drug targeting MET exon 14 mutations and is widely used in the treatment of non-small cell lung cancer (NSCLC). Although capmatinib shows good efficacy in many patients, some patients may develop resistance as treatment progresses. The occurrence of drug resistance is often related to the genetic variation of tumors, changes in drug metabolism pathways, and changes in the tumor microenvironment. When a patient develops resistance to capmatinib, the treatment plan needs to be adjusted promptly to continue to control disease progression and prolong survival.

After drug resistance, patients should undergo genetic testing as required to determine whether new genetic mutations have occurred. This is a critical step in determining subsequent treatment options. Through genetic testing, doctors can understand the tumor's response to drugs and choose more appropriate drugs or treatments.

If no other targetable mutations are found in the patient's tumor, chemotherapy may be a reasonable option. Traditional chemotherapy drugs such as platinum and paclitaxel can be used to control tumor growth. Although their effects may not be as obvious as targeted therapies, they can still bring certain clinical benefits in some cases. In addition, immunotherapy is also an option, especially when there is immune infiltration in the tumor microenvironment. Immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors may also provide patients with additional survival opportunities.

In addition to drug treatment, patients also need to pay attention to maintaining good living habits and dietary habits. In terms of diet, you should try to choose foods rich in high-quality protein, vitamins and minerals, such as eggs, milk, lean meat, fish, vegetables and fruits. These foods help provide the body with the nutrients it needs and enhance immunity to better cope with the challenges of cancer treatment.